We are α-D-Glucopyranoside, methyl 1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]- CAS:714269-57-5 manufacturer and supplier in China, Pls send inquiry of to firstname.lastname@example.org of visit www.nbinno.com our official website should you have any interests
Chemical Name: α-D-Glucopyranoside, methyl 1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-
Physical and Chemical Properties:
Boiling point: 609.6±55.0 °C at 760 mmHg
Melting point: /
Flash point: 322.5±31.5 °C
Refractive index: 1.628
Appearance:white crystalline powder
Moisture Content: ≤0.5%
25kg cardboard drum or according to customer specified requirements
Storage:Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:Intermediates of Dapagliflozin CAS:461432-26-8
Intermediates of Dapagliflozin Propanediol Monohydrate CAS:960404-48-2
Related News: U.S. drugmaker Gilead dominates the HIV market and it will keep up the pressure with fast-growing Biktarvy, which was approved early last year.2-Phenylacetamide Rigosertib, Onconova’s lead candidate, is a proprietary Phase 3 small molecule.1- (4-hidrazinofenil) metil-1,2,4-triazol CAS:212248-62-9 At the same time, experts said that API companies need to increase investment in environmental protection, carry out industrial upgrades, improve processes, improve pollution treatment capabilities, and then achieve sustainable development in the future, and seize structural opportunities.[dimethylamino-(2,3,4,5,6-pentafluorophenoxy)methylidene]-dimethylazanium,hexafluorophosphate The policy-oriented emphasis on the medical and pharmaceutical industries and the direct support for the chemical raw material pharmaceutical industry have created a good political environment for the development of related enterprises and laid the foundation for the rapid development of the chemical raw material pharmaceutical industry. The good development prospects of the chemical raw material pharmaceutical industry will be passed directly to the upstream raw material industry, which will help stimulate the demand for the pharmaceutical intermediate market.In April 2019, Glenmark had received approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate after successfully completing Phase-3 clinical trials.